Management Change/Compensation Form 8 K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 26, 2024, the board of directors (the "Board") of Verve Therapeutics, Inc. (the "Company") increased the size of the Board to nine members and, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, elected, effective immediately, Jodie Morrison as a member of the Board and as a member of the Compensation Committee of the Board and Ourania "Nia" Tatsis, Ph.D. as a member of the Board. Ms. Morrison was designated as a Class I director with a term expiring at the 2025 annual meeting of stockholders of the Company and thereafter until her successor has been duly elected and qualified, or until her earlier resignation or removal. The Board has determined that Ms. Morrison is "independent" as contemplated by the Nasdaq listing rules and other governing laws and applicable regulations. Dr. Tatsis was designated as a Class III director with a term expiring at the 2027 annual meeting of stockholders of the Company and thereafter until her successor has been duly elected and qualified, or until her earlier resignation or removal.

There are no arrangements or understandings between Ms. Morrison and any other person pursuant to which she was elected as a director. There are no transactions in which Ms. Morrison has an interest requiring disclosure under Item 404(a) of Regulation S-K ofthe Securities Act of 1933, as amended (the "Securities Act").

There are no arrangements or understandings between Dr. Tatsis and any other person pursuant to which she was elected as a director. Dr. Tatsis is an executive officer of Vertex Pharmaceuticals Incorporated ("Vertex"). The Company entered into a Strategic Collaboration and License Agreement with Vertex in July 2022, for an exclusive, four-year worldwide research collaboration focused on developing in vivogene editing candidates toward an undisclosed target for the treatment of a single liver disease. The Company received an upfront payment from Vertex of $25.0 million and is eligible to receive (i) success payments of up to $22.0 million for each product candidate (up to a maximum of $66.0 million) that achieves the applicable development criteria, (ii) up to an aggregate of $175.0 million in development milestones and (iii) up to an aggregate of $165.0 million in commercial milestone payments. The Company is also eligible to receive tiered single-digit royalties on net sales, with the rate dependent upon the type of product and subject to specified reductions. Vertex is obligated to reimburse the Company's research expenses consistent with a mutually agreed-upon research plan and budget. There are no other transactions in which Dr. Tatsis has an interest requiring disclosure under Item 404(a) of Regulation S-K ofthe Securities Act.

Ms. Morrison and Dr. Tatsis will each be compensated in the same manner as the Company's other non-employee directors.Information concerning the current compensation of the Company's directors is set forth in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "SEC") on April 26, 2024. Accordingly, Ms. Morrison and Dr. Tatsis each were granted, upon their election to the Board, an option to purchase 267,541 shares of common stock of the Company under the Company's 2021 Stock Incentive Plan, at an exercise price of $5.02 per share, the closing price per share of the Company's common stock on the Nasdaq Global Select Market on the effective date of their election. The options will vest in equal monthly installments following the grant date until the third anniversary of the grant date, subject to continued service as a director.

In connection with their election, each of Ms. Morrison and Dr. Tatsis has entered into the Company's standard form of Indemnification Agreement, a copy of which was filed as Exhibit 10.17 to the Company's Registration Statement on Form S-1 (File No. 333-256608) filedwith the SEC on May 28, 2021. Pursuant to the terms of this agreement, the Company may be required, among other things, to indemnify each of Ms. Morrison and Dr. Tatsis for some expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by them in any action or proceeding arising out of their service as a director of the Company.